Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
Recruitment status was: Recruiting
The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable.
In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays.
In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers.
We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.
|Latent Tuberculosis Infection||Procedure: Blood test for Quantiferon-GOLD assay|
|Study Design:||Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Please refer to this study by its ClinicalTrials.gov identifier: NCT00449345
|Contact: David Shitrit, MD||+972 8 946 firstname.lastname@example.org|
|Contact: Ben Fox, MRCP||+972 8 946 email@example.com|
|Community Tuberculosis service||Recruiting|
|Principal Investigator:||David Shitrit, MD||Maccabi Healthcare Services, Israel|